EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations (Q29615392)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

author name string

McCabe MT

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Ott HM

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Ganji G

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Korenchuk S

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Thompson C

5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Van Aller GS

6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Liu Y

7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Graves AP

8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Della Pietra A 3rd

9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Diaz E

10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

LaFrance LV

11

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Mellinger M

12

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Duquenne C

13

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Tian X

14

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Kruger RG

15

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

McHugh CF

16

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Brandt M

17

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Miller WH

18

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Dhanak D

19

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Verma SK

20

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Tummino PJ

21

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

Creasy CL

22

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

6 December 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

volume

492

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

issue

7427

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

30 April 2017

page(s)

108-12

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Analysis of the coding genome of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Many paths to methyltransfer: a chronicle of convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

A clustering approach for identification of enriched domains from histone modification ChIP-Seq data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Kinetic applications using high substrate and competitive inhibitor concentrations to determine Ki or Km.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE11606

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

21 January 2018

1 reference

12 December 2020

The roles of EZH2 in cell lineage commitment.

1 reference

12 December 2020

Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens

1 reference

12 December 2020

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker

1 reference

12 December 2020

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

1 reference

12 December 2020

A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations.

1 reference

12 December 2020

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

246237

1000463489

0 references

246237

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=23051747

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017